CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
Portfolio Pulse from
CSL Behring's gene therapy HEMGENIX shows sustained efficacy and safety in treating hemophilia B, with 94% of patients eliminating factor IX prophylaxis and maintaining near-normal factor IX levels four years post-treatment.
February 07, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CSL Behring's HEMGENIX gene therapy demonstrates long-term efficacy and safety in hemophilia B treatment, potentially boosting CSL's market position and stock value.
The positive long-term results of HEMGENIX in treating hemophilia B could enhance CSL's reputation and market position, likely leading to a positive impact on its stock price. The sustained efficacy and safety data are critical for investor confidence.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90